|
| Mechanism of Action |
| Requip is a Dopaminergic Agent |
Research over the past 2 decades has defined the symptoms of Restless Legs Syndrome (RLS) and is leading to the likelihood that the source of the problem is the brain, not the legs. Research has implicated an abnormality in the central dopaminergic pathways. [15]
Requip targets a proposed underlying cause of primary RLS. [15] |
Theorized Mechanism of Action Demonstrating How Dopamine Agonists Affect RLS
The precise mechanism of action with Requip, as treatment for RLS, is unknown. |
Requip is indicated for patients with moderate-to-severe primary RLS.
Requip has been associated with sedating effects, including somnolence, and the possibility of falling asleep while engaged in activities of daily living, including operation of a motor vehicle. Syncope or symptomatic hypotension may occur, particularly during initial treatment or dose titration. Impulse control symptoms, including pathological gambling and hypersexuality, have been reported in patients treated with dopaminergic agents, including ropinirole.
For More Safety Information about Requip, click here.
Complete Prescribing Information for Requip® (ropinirole HCl) Tablets
|
This site is intended for US healthcare professionals only.
© 1997-2008 GlaxoSmithKline. All Rights Reserved.
Legal Notices | Privacy Statement | Medicine Savings | Contact Us
|
|
|
Mechanism of Action
